Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine

[1]  J. Bobes,et al.  Recurrence of neuroleptic malignant syndrome. , 2013, Actas espanolas de psiquiatria.

[2]  A. Ziomber,et al.  Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures , 2012, Pharmacological reports : PR.

[3]  P. Bieńkowski,et al.  Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients , 2012 .

[4]  B. Berman.  Neuroleptic Malignant Syndrome , 2011, The Neurohospitalist.

[5]  Chun-Yen Chen,et al.  Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome. , 2011, General hospital psychiatry.

[6]  G. Fricchione,et al.  Neuroleptic malignant syndrome: further lessons from a case report. , 2010, Psychosomatics.

[7]  D. Dassa,et al.  Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  Shankar Kuchibatla,et al.  A case report of neuroleptic malignant syndrome , 2009, BMJ Case Reports.

[9]  R. Gebker,et al.  A rare case of neuroleptic malignant syndrome presenting with serious hyperthermia treated with a non-invasive cooling device: a case report , 2009, Journal of medical case reports.

[10]  T. Pollmächer,et al.  Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever , 2009, Psychoneuroendocrinology.

[11]  S. Englisch,et al.  Combined antipsychotic treatment involving clozapine and aripiprazole , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[12]  H. Ahmadkhaniha,et al.  Is Neuroleptic Malignant Syndrome Diagnostic Criteria Adequately Sensitive to Identify Diverse Features of the Syndrome , 2008 .

[13]  C. Corallo,et al.  Atypical neuroleptic malignant syndrome with long-term clozapine. , 2007, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[14]  Z. Herman,et al.  Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.

[15]  A. Francis,et al.  Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam , 2006, Neuropsychiatric disease and treatment.

[16]  R. C. Hall,et al.  Atypical Neuroleptic Malignant Syndrome Presenting as Fever of Unknown Origin in the Elderly , 2005, Southern medical journal.

[17]  Qiang Li,et al.  [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia]. , 2004, Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA.

[18]  C. Dinarello.  Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed , 2004, Journal of endotoxin research.

[19]  J. Ananth,et al.  Neuroleptic malignant syndrome and atypical antipsychotic drugs. , 2004, The Journal of clinical psychiatry.

[20]  P. Delespaul,et al.  Toxic rise of clozapine plasma concentrations in relation to inflammation , 2003, European Neuropsychopharmacology.

[21]  A. A. Romanovsky,et al.  The organum vasculosum laminae terminalis in immune-to-brain febrigenic signaling: a reappraisal of lesion experiments. , 2003, American journal of physiology. Regulatory, integrative and comparative physiology.

[22]  D. Soszyński.  [The pathogenesis and the adaptive value of fever]. , 2003, Postepy higieny i medycyny doswiadczalnej.

[23]  A. M. Baciewicz,et al.  Clozapine-associated neuroleptic malignant syndrome. , 2002, Annals of internal medicine.

[24]  R. Reeves,et al.  Atypical Neuroleptic Malignant Syndrome Associated with Olanzapine , 2002, Pharmacotherapy.

[25]  Huang Tl.  Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge. , 2001 .

[26]  T. Pollmächer,et al.  Effects of antipsychotic drugs on cytokine networks. , 2000, Journal of psychiatric research.

[27]  J. Vázquez-Barquero,et al.  Neuropletic malignant syndrome and olanzapine. , 2000, Journal of clinical psychopharmacology.

[28]  S. Stanfield,et al.  Neuroleptic malignant syndrome associated with olanzapine therapy: a case report. , 2000, The Journal of emergency medicine.

[29]  E. Leinonen,et al.  Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment , 2000, Acta psychiatrica Scandinavica.

[30]  P. Lestavel,et al.  Neuroleptic malignant syndrome. , 2000, British journal of anaesthesia.

[31]  V. Lehtinen,et al.  Striatal D2 dopamine receptor density and psychotic symptoms in schizophrenia: a longitudinal study , 2000, Schizophrenia Research.

[32]  Del D. Miller,et al.  Review and management of clozapine side effects. , 2000, The Journal of clinical psychiatry.

[33]  K. Ilett,et al.  Relapsing Vivax Malaria, Chloroquine Toxicity, Anxiety, or Alcohol Misuse? , 2000, The Annals of pharmacotherapy.

[34]  C. Alderman,et al.  Possible Neuroleptic Malignant Syndrome Associated with Olanzapine , 2000, The Annals of pharmacotherapy.

[35]  C. Blatteis,et al.  Complement and the pathogenesis of endotoxic fever , 2000, International journal of biometeorology.

[36]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. , 2000, Schizophrenia research.

[37]  A. Alao,et al.  Cybersuicide: the Internet and suicide. , 1999, The American journal of psychiatry.

[38]  E. Zeisberger.  From humoral fever to neuroimmunological control of fever , 1999 .

[39]  M. Castro-Fernández,et al.  Acute hepatitis due to ritodrine , 1999 .

[40]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. , 1999, Journal of psychiatric research.

[41]  G. Chouinard,et al.  Olanzapine-induced neuroleptic malignant syndrome with mental retardation. , 1999, The American journal of psychiatry.

[42]  S. Lippmann,et al.  Olanzapine and NMS. , 1999, Psychiatric services.

[43]  C. Stephenson,et al.  Psychopharmacology of olanzapine , 1999, British Journal of Psychiatry.

[44]  J. Karagianis,et al.  Clozapine-Associated Neuroleptic Malignant Syndrome: Two New Cases and a Review of the Literature , 1999, The Annals of pharmacotherapy.

[45]  C. Emborg.  [Neuroleptic malignant syndrome after treatment with olanzapine]. , 1999, Ugeskrift for laeger.

[46]  T. Landis,et al.  Olanzapine-induced neuroleptic malignant syndrome. , 1999, Archives of general psychiatry.

[47]  H. Meltzer.  Outcome in schizophrenia: beyond symptom reduction. , 1999, The Journal of clinical psychiatry.

[48]  P. R. M. Bittencourt,et al.  Síndrome neuroléptica maligna: relato de caso com recorrência associada ao uso de olanzapina , 1998 .

[49]  R. Hanel,et al.  [Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine]. , 1998, Arquivos de neuro-psiquiatria.

[50]  R. Coeytaux,et al.  Case report: possible neuroleptic malignant syndrome associated with olanzapine. , 1998, Journal of clinical psychopharmacology.

[51]  G. Bruxner,et al.  Neuroleptic Malignant Syndrome Associated with Olanzapine , 1998, The Australian and New Zealand journal of psychiatry.

[52]  C. Billington,et al.  Neuroleptic Malignant Syndrome Associated with Olanzapine , 1998, The Annals of pharmacotherapy.

[53]  F. Holsboer,et al.  Effects of Clozapine on In Vitro Immune Parameters: A Longitudinal Study in Clozapine-Treated Schizophrenic Patients , 1998, Neuropsychopharmacology.

[54]  T. Pollmächer,et al.  Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. , 1997, The American journal of psychiatry.

[55]  M. Cuesta,et al.  Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. , 1997, The Journal of clinical psychiatry.

[56]  A. Dalkılıç,et al.  Neuroleptic malignant syndrome following initiation of clozapine therapy. , 1997, The American journal of psychiatry.

[57]  M. Maj,et al.  Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment , 1997, Psychiatry Research.

[58]  G. Tollefson,et al.  Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. , 1997, The Journal of clinical psychiatry.

[59]  M. Székely,et al.  Hypothalamic prostaglandin E2 during lipopolysaccharide-induced fever in guinea pigs , 1996, Brain Research Bulletin.

[60]  T. Pollmächer,et al.  Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. , 1996, Journal of clinical psychopharmacology.

[61]  C. Blatteis,et al.  Interaction between norepinephrine and prostaglandin E2 in the preoptic area of guinea pigs. , 1996, The American journal of physiology.

[62]  Coles Em.  The use of etiology in DSM-IV. , 1996 .

[63]  L. Leon,et al.  The adaptive value of fever. , 1996, Infectious disease clinics of North America.

[64]  R. Ancill,et al.  Clozapine-induced neuroleptic malignant syndrome: clozapine monotherapy rechallenge in a case of previous NMS. , 1996, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[65]  T. Pollmächer,et al.  Sleep during clozapine-induced fever in a schizophrenic patient , 1995, Biological Psychiatry.

[66]  P. Sachdev,et al.  Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. , 1995, Journal of clinical psychopharmacology.

[67]  F. Frankenburg,et al.  Fever associated with clozapine administration. , 1995, The American journal of psychiatry.

[68]  K. Nisijima,et al.  Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. , 1995, Journal of psychiatric research.

[69]  J. Calabrese,et al.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. , 1995, Journal of psychiatric research.

[70]  W. Kozak.  Fever: A Possible Strategy for Membrane Homeostasis during Infection , 2015, Perspectives in biology and medicine.

[71]  M. Jann,et al.  Pharmacokinetics and Pharmacodynamics of Clozapine , 1993, Clinical pharmacokinetics.

[72]  R. Dantzer,et al.  Effects of interleukin-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat , 1992, Brain Research.

[73]  C. Blatteis.  Role of the OVLT in the febrile response to circulating pyrogens. , 1992, Progress in brain research.

[74]  M. Kluger.  Fever: Role of Pyrogens and Cryogens , 1991, Physiological reviews.

[75]  H. Besedovsky,et al.  Neuroendocrine and metabolic responses induced by Interleukin‐1 , 1987, Journal of neuroscience research.

[76]  F. Coceani,et al.  Prostaglandin E2 and fever: a continuing debate. , 1986, The Yale journal of biology and medicine.

[77]  J. Levenson.  Neuroleptic malignant syndrome. , 2007, The American journal of psychiatry.

[78]  P. Gunby.  Fever, Its Biology, Evolution, and Function , 1980 .

[79]  A. Blum,et al.  Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika – unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin* ** , 1972 .